Drugs / BG-68501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06257264 | Mar 2024 → Aug 2026 overdue | endometrial cancer, gastric cancer, gastroesophageal cancer, hormone receptor-positive breast cancer +5 | BeiGene | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | BeOne Medicines | Results BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 beonemedicines.com ↗ |
| 2025-05-22 | BeOne Medicines | Results BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors beonemedicines.com ↗
Early clinical activity for BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure, supporting its development as a next-line option for tumors with CDK2 dependency. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | BeOne Medicines | BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 beonemedicines.com ↗ |
| 2025-05-22 | BeOne Medicines | BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors beonemedicines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-68501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06257264 ↗ |
| Action | Inhibit | “a Selective CDK2 Inhibitor” NCT06257264 ↗ |
| Route | Oral | “Planned doses administered orally.” NCT06257264 ↗ |
| Target | CDK2 | “BG-68501, a Selective CDK2 Inhibitor” NCT06257264 ↗ |